2023
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
Senna M, Kwon O, Piraccini B, Sinclair R, Ball S, Ding Y, Chen Y, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatology And Therapy 2023, 13: 3209-3220. PMID: 37991697, PMCID: PMC10689319, DOI: 10.1007/s13555-023-01063-2.Peer-Reviewed Original ResearchHair regrowthClinical benefitAlopecia areataClinical meaningful improvementSevere alopecia areataWeeks of treatmentEmotional distressQuality of lifeBaricitinib treatmentAlopecia ToolClinical outcomesResponder subgroupHospital AnxietySkindex-16Depression ScaleSecondary measuresPatientsMeaningful improvementsIntermediate responseScalp hairWeeks
2020
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, King B, Thyssen J, Silverberg J, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman‐Yassky E, Beck L, Janes J, DeLozier A, Gamalo M, Brinker D, Cardillo T, Nunes F, Paller A, Wollenberg A, Reich K. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. British Journal Of Dermatology 2020, 183: 242-255. PMID: 31995838, DOI: 10.1111/bjd.18898.Peer-Reviewed Original ResearchConceptsSevere ADBREEZE-AD1BREEZE-AD2Topical corticosteroidsInadequate responseWeek 1Global assessmentConcomitant topical corticosteroidsSafety of baricitinibSignificant haematological changesCommon adverse eventsPhase II studyPrimary end pointSevere atopic dermatitisAtopic dermatitis severityInvestigator's Global AssessmentPhase III trialsSelective Janus kinase 1Weeks of treatmentNight-time awakeningsNew safety concernsDaily placeboMonotherapy trialsCardiovascular eventsGastrointestinal perforation
2015
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal Of The American Academy Of Dermatology 2015, 73: 395-399. PMID: 26194706, DOI: 10.1016/j.jaad.2015.06.045.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisAtopic dermatitisTofacitinib citrateBody surface area involvementEdema/papulationRecalcitrant atopic dermatitisAD indexSurface area involvementWeeks of treatmentPlacebo control groupAdverse eventsConsecutive patientsArea involvementStandard treatmentControl groupDermatitisSmall sample sizeTreatmentPatientsPossibility of biasSample sizeLichenificationCitrateErythemaScoring